Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717399 | 0.92 | MAPT (0.51) | RENCYP3A4CHRM2CHRM4TRPV1 | |
| SCHEMBL7331989 | 0.84 | AOC3 (0.47) | RENCYP3A4CHRM2CHRM4TRPV1 | |
| SCHEMBL21248553 | 0.83 | CHRM2 (0.65) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL23455373 | 0.82 | MAPT (0.60) | RENCYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL6717411 | 0.81 | HRH3 (0.50) | RENCYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL6684778 | 0.81 | CHRM2 (0.52) | RENCYP3A4CHRM2CHRM4TRPV1 | |
| SCHEMBL6721739 | 0.80 | CHRM2 (0.54) | RENCYP3A4CHRM2CHRM4TRPV1 | |
| SCHEMBL29452159 | 0.80 | CHRM2 (0.51) | RENCYP3A4CHRM2CHRM4TRPV1 | |
| SCHEMBL25279962 | 0.80 | CHRM2 (0.51) | RENCYP3A4CHRM2CHRM4TRPV1 | |
| SCHEMBL6717277 | 0.80 | CHRM2 (0.56) | RENCYP3A4CHRM2CHRM4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | REN 1/4885CYP3A4 1308/4885CHRM2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.